Is there a role for botulinum toxin in the treatment of migraine?

Current Pain and Headache Reports

Volumn 7, Issue 3, 2003, Pages 229-234

  Evers, Stefan ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; ANTIPARKINSON AGENT; BOTULINUM TOXIN;

ACUPUNCTURE; CLINICAL STUDY; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL DESIGN; HUMAN; MIGRAINE; NOCICEPTION; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; MIGRAINE DISORDERS;

EID: 0038167467     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-003-0078-1     Document Type: Review

References (34)

1. Tfelt-Hansen P, Block G, Dahlöf C, et al.: International Headache Society Clinical Trials Subcommittee: guidelines for controlled trials of drugs in migraine, edn 2. Cephalalgia 2000, 20:765-786.
2. Schoenen J: Guidelines for trials of drug treatments in tension-type headache: First Edition. Cephalalgia 1995, 15:165-179.
3. Silberstein SD: Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2001, 2:1649-1654.
4. Binder WJ, Brin MF, Blitzer A, Pogoda JM: Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon 2002, 48:323-335.
5. Mauskop A: The use of botulinum toxin in the treatment of headaches. Curr Pain Headache Rep 2002, 6:320-323.
6. Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW: Treatment of headache with botulinum toxin A: a review according to evidence-based medicine criteria. Cephalalgia 2002, 22:699-710.
7. Göbel H, Heinze A, Heinze-Kuhn K, Jost WH: Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol 2001, 248(suppl 1):34-38.
8. Mathew NT, Kaup AO: The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 2002, 4:365-373.
9. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988, 8(suppl 7):1-92.
10. Krusz J: Intradermal Botulinum toxin, type A, treatment for cervicogenic migraine. Eur J Neurol 2002, 9(suppl 2):158.
11. Krusz J: Intradermal botulinum toxin, type B, treatment for cervicogenic migraine. Eur J Neurol 2002, 9(suppl 2): 188.
12. Fadeyi MO, Adams QM: Use of botulinum toxin type B for migraine and tension headaches. Am J Health Syst Pharm 2002, 59:1860-1862.
13. Silberstein S, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445-450.
14. Brin MF, Swope DM, O'Brian C, et al.: Botox, for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 2000, 20:421-422.
15. Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669-676.
16. Mauskop A, Basdeo R: Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalalgia 2000, 20:422.
17. Smuts JA, Barnard PWA: Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalalgia 2000, 20:332-337.
18. Guyuron B, Tucker T, Davis J: Surgical treatment of migraine headaches. Plast Reconstr Surg 2002, 109:2183-2189.
19. Robbins L: Botulinum toxin A for refractory chronic daily headache. Neurology 2001, 56(suppl 3):A349.
20. Wheeler AH: Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998, 38:468-471.
21. Klapper JA, Mathew NT, Klapper A, Kailasam J: Botulinum toxin type A (BTX-A) for the prophylaxis of chronic daily headache. Cephalalgia 2000, 20:291-292.
22. Poungvarin N: The first world report of botulinum A toxin injection for status migrainosus. J Med Assoc Thai 2001, 84:1199-1203.
23. Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999, 3:427-431.
24. Ceballos-Baumann AO, Petri S, Toelle T, et al.: Neues in der Botulinum toxin-Therapie: Von der Dystonie bis zur Migrä neprophylaxe. Nervenheilkunde 2001, 20:151-157.
25. Pacchetti C, Albani G, Martignoni E, et al.: "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995, 10:333-336.
26. Wissel J, Müller J, Dressnandt J, et al.: Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000, 20:44-49.
27. Barwood S, Baillieu C, Boyd R, et al.: Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000, 42:116-121.
28. Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400-404.
29. Rosales RL, Arimura K, Ikenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 1996, 19:488-496.
30. Blersch W, Schulte-Mattler WJ, Przywara S, et al.: Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002, 205:59-63.
31. Wiegand H, Erdmann G, Wellhöner HH: 125I-labelled botulinum A neurotoxin: pharmacokinetics on cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1977, 298:235-238.
32. Verderio C, Coco S, Rossetto O, et al.: Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. J Neurochem 1999, 73:372-379.
33. Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245-258.
34. Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.